戻る Agenda
Session 9BC: Expanding Therapeutic Utility via Targeted Delivery
Session Chair(s)
Patrik Andersson, PHD
Principal Scientist, Discovery Safety Specialist, AstraZeneca R&D, Sweden
This joint preclinical/clinical session will present novel translational insights of GalNAc-conjugated ASOs as well as novel targeting strategies for increasing productive uptake into cell types that normally are challenging to reach with oligonucleotide therapeutics. These include muscle and immune cells as well as pancreatic islets. The presentations will be followed by a 30 minute panel discussion. Discussion topics include:
Learning Objective : Recognize the opportunities and challenges of developing novel targeting approaches
Speaker(s)
Sree Rayavarapu, DVM, PHD
Toxicologist, FDA, United States
Session Co-Chair
Wouter Driessen, PHD, MS
DMPK Project Leader , F. Hoffmann-La Roche AG, Switzerland
Translational Development of a GalNAC-Conjugated LNA-Based Single Stranded Oligonucleotide
Arthur A. Levin, PHD
Distinguished Scientist, Avidity Biosciences, United States
Oligonucleotide Therapeutics Now on Target
Patrik Andersson, PHD
Principal Scientist, Discovery Safety Specialist, AstraZeneca R&D, Sweden
Targeting Antisense Oligonucleotides to Pancreatic Islets
Panel Discussion
, All Session Speakers, United States